NRDC wants FDA to act on BPA
This article was originally published in The Tan Sheet
Executive Summary
The Natural Resources Defense Council requests a court order compelling FDA to act on the council's petition to ban the use of bisphenol A in food packaging and other materials likely to contact food. NRDC, which filed the complaint June 29 in the U.S. Court of Appeals for the D.C. Circuit, petitioned FDA in October 2008 to prohibit BPA, a hormone-disrupting chemical, in food packaging. FDA officials expressed concern about the effects of early life exposure to BPA on brain development and the prostate gland of fetuses, infants and children (1"The Tan Sheet" Jan. 25, 2010). When the agency noted that a National Institutes of Health's National Toxicology Program expressed "concern for effects of the substance on the brain, behavior and prostate gland in fetuses, infants and children at current human exposures," makers of infant formula sought substitutes to BPA use in can linings (2"The Tan Sheet" March 1, 2010)
You may also be interested in...
FDA Shift On BPA May Tighten Squeeze On Infant Formula Manufacturers
FDA's shift in position regarding the safety of bisphenol A likely will expedite the trend toward BPA-free packaging among infant formula marketers, even though existing science does not demonstrate a proven threat to babies and children
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.